Print

U.S. FDA Approves Bristol-Myers Squibb Company (BMY) Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)  
5/15/2012 9:53:04 AM

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA® (abatacept).
//-->